-
Featured
Maximizing Clinical Utility of Pulmonary Optical Imaging
Massachusetts General Hospital researchers push the limits of pulmonary optical frequency domain imaging for in vivo diagnosis of lung cancer and assessment of asthmatic airways.
-
Revolutionizing Palliative Care Delivery and Access to Improve Outcomes for Patients and Caregivers
Research at Massachusetts General Hospital is shifting how integrated palliative and oncology care is delivered to support patients with cancer and caregivers.
-
ASCO 2024 Meeting Highlights
Priscilla Brastianos, MD, Lecia Sequist, MD, MPH, and Jessica Lin, MD, share highlights from the ASCO 2024 conference, including encouraging results from a clinical trial for patients with high grade meningiomas, a new treatment for stage III unresectable EGFR lung cancer, and a palliative care trial.
-
Molecular Features Identified That Predict Response to Checkpoint Inhibitors in NSCLC
Justin Gainor, MD, and colleagues have published findings from the first joint analysis of the Stand Up To Cancer–Mark Foundation non-small cell lung cancer cohort, reporting newly identified genomic and transcriptomic biomarkers of response and resistance to anti–PD-1 and anti–PD-L1 immune checkpoint inhibitors.
-
Lymph Node Harvest, Upstaging After Lobectomy for NSCLC Linked to Hospital Volume
Henning A. Gaissert, MD, and colleagues reviewed a Society of Thoracic Surgeons database for 2012 to 2019 and report increased likelihood of nodal upstaging at hospitals that perform a low annual volume of lobectomies for non–small-cell lung cancer—but 25% of high-volume centers failed to harvest ≥10 nodes on average.
-
Pulmonary Function at Time of Lung Cancer Diagnosis Has Prognostic Value
David C. Christiani, MD, MPH, and colleagues found in a large cohort of patients newly diagnosed with non–small-cell lung cancer that poorer spirometry results were linearly associated with worse survival, even after accounting for age, sex, smoking status, tumor histology, cancer stage, and types of treatment.
Lung Cancer Contributors
-
Aaron Hata, MD, PhD
Assistant Physician, Hematology and Oncology, Massachusetts General Hospital, Assistant Professor of Medicine, Harvard Medical School
Recent Article
Study Provides Insight Into Overcoming Acquired Resistance to KRAS-G12C Inhibitors
-
Aaron L. Baggish, MD
Director, Cardiovascular Performance Program, Director, Cardiovascular Performance Program Fellowship
Recent Article
How COVID-19 Affects the Heart, Especially in Athletes
-
Gary X. Wang, MD, PhD
Diagnostic Radiologist, Department of Radiology, Massachusetts General Hospital
Recent Article
Some Physicians Knowingly Order Guideline-Discordant Lung Cancer Screening -
Melissa J. Suter, PhD
Associate Professor in Medicine, Harvard Medical School, Assistant in Biomedical Engineering, Massachusetts General Hospital
Recent Article
Maximizing Clinical Utility of Pulmonary Optical Imaging -
Michael T. Lu, MD, MPH
Director of Research, Cardiovascular Imaging Division, Co-Director, Cardiovascular Imaging Research Center, Massachusetts General Hospital, Assistant Professor of Radiology, Harvard Medical School
Recent Article
Q&A: AI Predicts 10-Year Risk of Heart Attack and Stroke from X-Ray Images -
Rebecca Suk Heist, MD, MPH
Professor of Medicine at Harvard Medical School, Interim Vice Chief, Clinical Research, Division of Hematology/Oncology, Mass General Cancer Center
Recent Article
Study Provides Insight Into Overcoming Acquired Resistance to KRAS-G12C Inhibitors
-
Udo Hoffmann, MD
Director, Cardiac MR PET CT Program, Mass General, Division Chief, Cardiovascular Imaging, Mass General, Professor of Radiology, HMS
Recent Article
Discordance Across High-Sensitivity Troponin Assays Can Affect Management of Suspected ACS
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
